MARKET

ALNY

ALNY

Alnylam Pharmaceuticals Inc
NASDAQ
322.98
+2.98
+0.93%
After Hours: 321.68 -1.3 -0.40% 19:37 02/10 EST
OPEN
322.68
PREV CLOSE
320.00
HIGH
325.98
LOW
317.89
VOLUME
1.87M
TURNOVER
--
52 WEEK HIGH
495.55
52 WEEK LOW
205.87
MARKET CAP
42.67B
P/E (TTM)
1412.24
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at ALNY last week (0202-0206)?
Weekly Report · 1d ago
A Look At Alnylam Pharmaceuticals (ALNY) Valuation After New Revenue Outlook And Long Term Growth Targets
Simply Wall St · 6d ago
LIVE MARKETS-LPL Financial now among possible S&P 500 additions 
Reuters · 02/02 17:06
Weekly Report: what happened at ALNY last week (0126-0130)?
Weekly Report · 02/02 10:10
Has The Recent Pullback In Alnylam Pharmaceuticals (ALNY) Opened A Valuation Opportunity?
Simply Wall St · 01/30 20:31
Alnylam Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Dow Jones · 01/30 17:00
Alnylam Pharmaceuticals Price Target Cut to $408.00/Share From $495.00 by Morgan Stanley
Dow Jones · 01/30 17:00
Morgan Stanley Maintains Equal-Weight on Alnylam Pharmaceuticals, Lowers Price Target to $408
Benzinga · 01/30 16:50
More
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.

Webull offers Alnylam Pharmaceuticals, Inc. stock information, including NASDAQ: ALNY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ALNY stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ALNY stock methods without spending real money on the virtual paper trading platform.